TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment of Progressive or Recurrent Hepatocellular Carcinoma
Source: Childhood Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: January 6, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
The prognosis for a patient with recurrent or progressive hepatocellular carcinoma is extremely poor.[50]
Source links and citations
Treatment options for progressive or recurrent hepatocellular carcinoma include the following:
Chemoembolization temporization before transplant or immediate liver transplant, for those with isolated recurrence in the liver.[25,35,36,51]
Radiofrequency ablation.In a retrospective single-institution study, ten children aged 6 to 17 years with recurrent hepatocellular carcinoma were treated with radiofrequency ablation. After one ablation, 14 of 15 target lesions had complete responses. None of these lesions progressed. The 1-year OS rate was 77.8%, and the 3-year OS rate was 44.4%.[52][Level of evidence C1]
Source links and citations
Phase I and phase II clinical trials may be appropriate and should be considered.
Treatment with sorafenib has resulted in improved progression-free survival in adults with advanced hepatocellular carcinoma. For adult patients who received sorafenib, the median survival and time to radiological progression were about 3 months longer than for patients who received a placebo.[53]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice